FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average b	ourden							
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Last) C/O CRI	Brendan (Fi SPR THER	APEUTICS, IN	(Middle) C.		2. Issuer Name and Ticker or Trading Symbol CRISPR Therapeutics AG [CRSP] 3. Date of Earliest Transaction (Month/Day/Year) 10/14/2021							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) Chief Financial Officer					
(Street) CAMBR (City)		A	02139 (Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year)						Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
1. Title of Security (Instr. 3) 2. Transa Date			. Transac	action Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transacti Code (Ins	4. Section Dispositr. 5)	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4)		or 5. Amount of		s Form (D) of (I) (In (ion(s)		: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	Title of 2. 3. Transaction 3A. Deemed Execution Date Execution Date, or Exercise (Month/Day/Year) if any		Co	ransaction of ode (Instr. Derivative		Expiration Date (Month/Day/Year) U		of Secu Underli Derivati	7. Title and Amour of Securities Underlying Derivative Security (Instr. 3 and 4)		Price of erivative ecurity istr. 5)			10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Co	de V	(A)	(D)	Date Exercisable	Expiration Date	ı Title	Amou or Numb of Share	er					
Restricted Stock Units	(1)	10/14/2021		A		15,000		(2)	(2)	Commo Share		00	\$0.00	15,000		D	
Stock Option (Right to Buy)	\$98.7	10/14/2021		A		90,000		(3)	10/14/203	1 Commo		00	\$0.00	90,000		D	

Explanation of Responses:

- 1. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
- 2. This restricted stock unit award was granted on October 14, 2021 with respect to 15,000 Common Shares, with (i) one quarter of the shares vesting on October 14, 2022, (ii) one quarter of the shares vesting on October 14, 2023, (iii) one quarter of the shares vesting on October 14, 2025.
- 3. This option was granted on October 14, 2021 with respect to 90,000 Common Shares, with 25% of the shares vesting on October 14, 2022 and the remaining shares vesting on each monthly anniversary thereafter for a period of 36 months.

Remarks:

/s/ Michael Esposito, attorneyin-fact

** Signature of Reporting Person Date

10/18/2021

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.